Evidence map›Paper›PMID 33125468›Full record

ReviewEndocrine reviews2021

Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease.

William B Horton, Eugene J Barrett

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrine reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
218citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

218 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Effect of diabetes on the efficacy and safety ofJournal of ginseng research · 2026
    Article
  20. Article

158 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

William B HortonDivision of Endocrinology and Metabolism, Department of Medicine.
Eugene J BarrettDivision of Endocrinology and Metabolism, Department of Medicine.

Funding

The integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve HealthUL1TR003015 · NCATS · UNIVERSITY OF VIRGINIA · PI Donald E Brown, KAREN C. JOHNSTON · 2022 to 2023
$9.1M
Institutional Career Development CoreKL2TR003016 · NCATS · UNIVERSITY OF VIRGINIA · PI Jason Papin, BRADFORD B WORRALL · 2022 to 2023
$2.1M
Acute effects of hyperglycemia on heart and skeletal muscle microvasculatureR01HL142250 · NHLBI · UNIVERSITY OF VIRGINIA · PI EUGENE Joseph BARRETT · 2022 to 2022
$737k
Interdisciplinary Training in Systems & Biomolecular Data ScienceT32GM145443 · UNIVERSITY OF VIRGINIA · 2025 to 2025
$321k
NCATS NIH HHS KL2 TR003016NCATS NIH HHS UL1 TR003015NHLBI NIH HHS F32 HL142304NHLBI NIH HHS R01 HL142250NIGMS NIH HHS T32 GM145443
6 · The paper itself

Abstract

This review takes an inclusive approach to microvascular dysfunction in diabetes mellitus and cardiometabolic disease. In virtually every organ, dynamic interactions between the microvasculature and resident tissue elements normally modulate vascular and tissue function in a homeostatic fashion. This regulation is disordered by diabetes mellitus, by hypertension, by obesity, and by dyslipidemia individually (or combined in cardiometabolic disease), with dysfunction serving as an early marker of change. In particular, we suggest that the familiar retinal, renal, and neural complications of diabetes mellitus are late-stage manifestations of microvascular injury that begins years earlier and is often abetted by other cardiometabolic disease elements (eg, hypertension, obesity, dyslipidemia). We focus on evidence that microvascular dysfunction precedes anatomic microvascular disease in these organs as well as in heart, muscle, and brain. We suggest that early on, diabetes mellitus and/or cardiometabolic disease can each cause reversible microvascular injury with accompanying dysfunction, which in time may or may not become irreversible and anatomically identifiable disease (eg, vascular basement membrane thickening, capillary rarefaction, pericyte loss, etc.). Consequences can include the familiar vision loss, renal insufficiency, and neuropathy, but also heart failure, sarcopenia, cognitive impairment, and escalating metabolic dysfunction. Our understanding of normal microvascular function and early dysfunction is rapidly evolving, aided by innovative genetic and imaging tools. This is leading, in tissues like the retina, to testing novel preventive interventions at early, reversible stages of microvascular injury. Great hope lies in the possibility that some of these interventions may develop into effective therapies.

Indexed as

AnimalsDiabetes MellitusDyslipidemiasHumansHypertensionMicrovesselsObesitycardiometabolic diseasediabetes complicationsdiabetes mellitusmicrovascular rarefactionmicrovesselsvascular endothelium

Identifiers

PMID33125468
PMCPMC7846151

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.